Abstract. Human epidermal growth factor 2 (HER2) positivity rates for gastric or gastroesophageal junction (GEJ) adenocarcinoma have been reported at 15-25%. Cyclin D1 (BCL1) is a non-specific proliferative marker. The prognostic significance of HER2 and cyclin D1 is inconclusive, with contradictory data. The aim of this study was to evaluate the incidence of HER2 overexpression in gastric or GEJ patients. The presence of a possible correlation between HER2 status and cyclin D1 staining was assessed; both were evaluated as prognostic markers for survival. The clinical data and histological specimens of 150 consecutive patients diagnosed with gastric or GEJ adenocarcinoma, and treated at our hospital from June 2005 to March 2009, were analyzed. Pathological specimens were immunohistochemically stained for HER2. Immunoreactivity was determined according to the scoring system for gastric carcinoma. Cyclin D1 immunoreactivity was also tested. The results demonstrated that HER2 was positive in 14/150 (9.3%) patients. HER2-positive (HER2+) and HER2-negative (HER2-) patients did not differ significantly with regard to other clinicopathological parameters. In a multivariate analysis, HER2 positivity was revealed to be a poor prognosis variable (P=0.046; 95% CI, 1.03-3.58). In patients with non-metastatic disease, median survival was 59 months for HER2+ and 42 months for HER2- patients, but this difference was not significant. In patients with metastatic disease, median survival was 9.5 months and 2.5 months for HER2+ and HER2- patients, respectively (P=0.041). Cyclin D1 was not idemonstrated to be a prognostic factor and was not associated with HER2 overexpression. The rate of positive HER2 status in the current group of unselected patients with gastric and GEJ adenocarcinoma was relatively low compared with that observed in the literature. Nevertheless, HER2 positivity was associated with a poor prognosis.

Introduction

Gastric or gastroesophageal junction (GEJ) adenocarcinoma represents a global health problem. In industrialized countries, the incidence of GEJ and gastric cardial cancers continues to rise, while noncardial gastric cancers have declined over the past few decades. In Israel, the incidence of gastric cancer has remained stable throughout the last decade, annually affecting 650-700 new patients. The incidence trend, described as the age standardized rate (ASR/100,000), is declining in the Jewish population, while rising in the Arab population (1).

The human epidermal growth factor 2 (HER2) gene is a well-described proto-oncogene. High amplification of this gene induces protein overexpression in the cellular membrane, conferring oncogenic properties to a malignant cell (2). Although HER2 gene amplification and protein overexpression have been mostly studied in breast cancer, a wide overexpression variation has been demonstrated in other malignancies (3). HER2 overexpression, measured using immunohistochemistry (IHC), was reported in 4-53% of gastric adenocarcinoma cases, with a median of 18% (4). In a previous study, the incidence of HER2/neu gene amplification was revealed to be higher in GEJ tumors compared with other gastric tumors, and in an intestinal histologic subtype compared with a diffused subtype (5). A recently published systematic review was inconclusive with regard to the prognostic association between HER2 overexpression and poorer survival in patients who underwent curative surgery (4).

The standard of care in advanced gastric carcinoma patients has changed recently, due to a phase III trial adding trastuzumab to chemotherapy in patients with overexpression of HER2 (ToGA trial). The study indicated that this subgroup of patients would benefit from an improvement in overall survival of almost three months (6).

The retinoblastoma (Rb) protein is a tumor suppressor protein that is dysfunctional in many cancers, including gastric...
adenocarcinoma. One function of phosphorylated Rb (pRb) is to prevent excessive cell growth by inhibiting cell cycle progression in the G1-S checkpoints. Cyclin D1 is a component of this pathway, and it stimulates phosphorylation of the Rb protein by associating with cyclin-dependent kinases (CDKs). Overexpression of cyclin D1 causes pRb pathway dysfunction and stimulation of cell proliferation (7). Upregulation of cyclin D1 has been described in gastric cancer; however, its prognostic value is not fully clear. A possible correlation between HER2 and cyclin D1, both suggested to be poor prognostic tissue markers, had not been examined prior to this study. 

The aim of the current study was to evaluate the incidence and the prognostic value of HER2 overexpression among an Israeli population with gastric or GEJ adenocarcinoma. In addition, the correlation between HER2 and cyclin D1 in this patient population was also investigated.

Materials and methods

Patients. The records and histological specimens of consecutive gastric or GEJ adenocarcinoma patients who had undergone surgery or biopsies, and were treated in the Division of Oncology at Rambam Healthcare Campus (Haifa, Israel) from June 2005 to March 2009, were evaluated. Clinical and demographical data were retrospectively collected from the computerized hospital medical charts. Data included location of the primary tumor, TNM staging, histological subtype, perineural or vascular invasion, type of surgery, adjuvant chemotherapy and/or radiotherapy, time to recurrence, site of metastases, chemotherapy regimens, response to treatment, time to tumor progression and survival. The study was conducted in accordance with the Helsinki declaration and approved by the Rambam Health Care Campus Ethics Committee, Bat-Galim, Haifa, Israel.

Immunohistochemical staining. All specimens were fixed in buffered formalin and were immunohistochemically stained for HER2 using the polyclonal antibody anti c-erbB-2 (dilution 1:1400; Dako; Glostrup, Denmark). Immunoreactivity was determined according to the scoring system for gastric carcinoma. For validation, certain cases were evaluated with the Ventana PATHWAY anti-HER-2/neu (4B5) rabbit monoclonal primary antibody (Ventana Medical Systems, Inc., Tucson, AZ, USA). Cases that scored 2+ were further evaluated using the HER2 CISH pharmDx kit (Dako). Additionally, cases were evaluated for cyclin D1 immunoreactivity using the rabbit monoclonal anti-cyclin D1 (SP4) antibody (dilution 1:90; Lab Vision/Neomarkers; Fremont, CA, USA). All immunostaining was performed in the Ventana Benchmark XT immunostainer (Ventana Medical Systems, Inc.). Positive controls, for HER2 (breast cancer) and cyclin D1 (mantel cell lymphoma), and negative controls were run in parallel. A total of 24 biopsy specimens (16%) were compared with surgical specimens.

Statistical methodology. To identify parameters associated with HER2 overexpression, binary logistic regression was implemented, including calculation of odds ratios (OR) with 95% confidence intervals (CI) and P-values in the bivariate analysis. Survival analysis was performed by the Kaplan-Meier method for overall survival (OS), according to HER2 in locoregional and metastatic diseases. To identify parameters associated with the OS bi-variant, Cox regression was used. P-values, hazard ratios (HR) and 95% CI were presented.

All variables with P<0.2 in bivariate analyses were included in a multivariable explanatory model. A multivariate analysis (Cox regression model) was utilized to determine the independent effects of variables on overall survival. The likelihood ratio was used as a measure of model discrimination. To analyze the difference between biopsy and surgery histology parameter results, the χ-coefficient was used. A two-tailed P≤0.05 was considered to indicate a statistically significant difference. Statistical analyses were performed with Statistics Products Solutions Services (SPSS) 18.0 software for Windows (SPSS, Inc.; Chicago, IL, USA).

Results

General remarks. The key demographic and clinical characteristics of patients are summarized in Table I One hundred and fifty patients, 59% of which were male, were included in the study. The median age at diagnosis was 65 years and 52 (30%) patients were over the age of 70. Arabs constituted 23% of the study population. Poorly differentiated or signet ring cell carcinoma was present in 65% of patients. The disease was metastatic in 68 (45%) patients and signet ring cell carcinoma was the most common histological subtype.

All 150 histological specimens of gastric carcinoma were immunohistochemically stained for HER2 and cyclin D1 immunoreactivity, as described previously (Fig. 1). In 24 cases, the biopsy specimens were compared to the surgical specimens. Only 14 (9.4%) specimens were HER2-positive (HER2+). Among the positive specimens, 11 exhibited an IHC HER2 score of +3, while three out of six cases with an IHC score of +2 demonstrated HER2 amplification in the CISH test. All demographic, histopathological and clinical parameters were tested for association with HER2+; however, no significant correlation was identified between HER2+ tumors and any of the parameters evaluated (Table I).

HER2 status in association with stage and survival. HER2+ status was identified in 7/82 (8.5%) patients with stage I-III adenocarcinoma who were treated with curative intent, and in 7/68 (10.3%) cases with stage IV adenocarcinoma. In the metastatic group, median survival was 9.5 and 2.5 months for HER2-negative (HER2-) and HER2+ patients, respectively.
(P=0.041). First-line therapy consisted of platinum and 5FU/capecitabine, with or without taxanes. No HER2+ patients were treated with trastuzumab. In the non-metastatic group, median survival time was 59 months for HER2- and 42 months for HER2+ patients, and this difference was not statistically different. In this group, 63 patients were in stage II-III and 19 in stage I of the disease. Adjuvant chemo-radiotherapy was given to 53 out of 63 patients.

**Prognostic factors for survival.** A Cox regression model was utilized to determine the independent effects of variables on overall survival. In a bivariate analysis (Table II), stage level was included in the model with P<0.001 (HR, 4.1). The other variables, with P<0.2 in the bivariate analyses, were HER2+ (P=0.10; HR, 1.7) and age over 70 years (P=0.19; HR, 1.45). These parameters were also included in the multivariable explanatory model. For illustration of the model, 1- and 2-year mortality were added to Table II. In the Cox regression multivariable analysis, together with stage (stage II-III: HR, 3.38; 95% CI, 1.2-9.5 and stage IV: HR, 1.73; 95% CI, 4.25-32.50), HER2+ was also revealed to be an independent negative prognostic factor for survival (HR, 1.2; 95% CI, 1.03-3.58; P=0.046), although the positive HER2 group was a small sample size.

**Cyclin D1 and validation tests.** Due to the low incidence of HER2+ in the study population when the anti-c-erbB2 oncoprotein antibody was used, a sample of 15 cases with an HER2 score of +1 or +2 was also evaluated with the Ventana PATHWAY anti-HER-2/neu (4B5) rabbit monoclonal primary antibody, for validation. Although the staining with the Ventana PATHWAY anti-HER2/neu (4B5) antibody was clearer for evaluation, no difference in the scoring level was observed between the two staining antibodies.

The majority of cases (89.3%) were cyclin D1-positive (≥5% staining of tumor cells). Only 16 cases had ≤5% cell staining; all of which were HER2-, and only 2 of which had a weak HER2 staining score of +1. No association was identified between HER2 status and cyclin D1. A threshold of 50% cell

| Variable | No. of patients | HER2 | Odds ratio | 95% confidence interval | P-value |
|----------|----------------|------|------------|-------------------------|---------|
| Gender   |                |      |            |                         |         |
| Male     | 89 (59%)       | 10 (11%) | 1.00      | Reference               | 0.34    |
| Female   | 61 (41%)       | 4 (6.6%) | 0.55      | 0.16-1.85               | 0.13    |
| Age (years) |            |      |            |                         |         |
| ≤50      | 27 (18%)       | 3 (11%) | 1.00      | Reference               | 0.13    |
| 51-70    | 71 (47%)       | 3 (4.2%) | 0.35      | 0.67-1.87               | 0.22    |
| ≥71      | 52 (35%)       | 8 (15.4%) | 1.45      | 0.30-6.00               | 0.60    |
| Ethnicity|                |      |            |                         |         |
| Jewish   | 116 (77%)      | 12 (10.4%) | 1.00    | Reference               | 0.48    |
| Arab     | 34 (23%)       | 2 (6.3%) | 0.57      | 0.12-2.67               |         |
| Histology|                |      |            |                         |         |
| Well diff.| 10 (7%)        | 0     |           |                         | 0.16    |
| Moderate diff. | 31 (21%) | 7 (22.6%) |           |                         |         |
| Signet ring and poor diff. | 96 (65%) | 7 (7.2%) |           |                         |         |
| Mucinous | 13 (8%)        | 0     |           |                         |         |
| Stage    |                |      |            |                         |         |
| I        | 19 (13%)       | 1 (5.3%) | 1.00      | Reference               | 0.80    |
| II and III | 63 (42%)      | 6 (9.5%) | 1.90      | 0.21-16.8               | 0.56    |
| IV       | 68 (45%)       | 7 (10.3%) | 2.06      | 0.24-17.91              | 0.51    |
| Location |                |      |            |                         |         |
| GEJ and cardia | 47 (31%) | 5 (10.4%) | 1.20      | 0.38-3.80               | 0.75    |
| Body     | 52 (35%)       | 4 (7.3%) | 0.66      | 0.20-2.25               | 0.51    |
| Antrum   | 46 (31%)       | 5 (10.6%) | 1.24      | 0.39-3.93               | 0.71    |
| Entire stomach | 5 (3%)  | 0     | 0.999     |                         |         |
| Cyclin D1|                |      |            |                         |         |
| ≤5%      | 15 (10%)       | 0     |           |                         | 0.69    |
| 6-49%    | 72 (48%)       | 9 (12.5%) |           |                         |         |
| ≥50%     | 63 (42%)       | 5 (8%) |           |                         |         |

HER2, human epidermal growth factor 2; diff., differentiated; GEJ, gastroesophageal junction.
staining was used to differentiate between positive and highly positive cyclin D1 staining. No correlation was observed between the level of cyclin D1 positive staining and any of the clinicopathological parameters or survival. Among the 134 positive cases, 71 (47.3%) cases exhibited positive staining (5%<cyclin D1<50%) and 63 (42%) were highly positive (>50% of the tumor cells).

The possibility of a difference in HER2 score or cyclin D1 staining between primary biopsies and surgical specimens was evaluated in 24 cases. No significant differences were observed in HER2 status or score between specimens. Heterogeneity was observed in the cyclin D1 level, while 52% of duplicated cases were not in the same cyclin D1 level group, with a κ value of 0.14 that indicated a slight degree of association.

Discussion

The prognostic value of HER2 gene amplification and protein overexpression in gastric adenocarcinoma is not as established as it is in breast cancer. In a retrospective study in Singapore, the rate of HER2 overexpression in patients who underwent curative surgery was 9.4% and was inversely correlated with survival in intestinal-type gastric cancer (8). However, a large retrospective study of over 900 cases identified similar rates of positive HER2 cases (<10%), but no correlation with survival was observed (9). A review of 35 published studies, which evaluated the prognostic value of HER2, indicated no differences in the majority of studies, with regard to overall survival (OS). Two studies identified a longer OS, while 13 (37%) observed a significantly poorer OS (4). The current study supports the data indicating that HER2 overexpression in gastric cancer is a poor prognostic sign.

A retrospective study involving 461 consecutive patients with gastric cancer evaluated the clinical and pathological characteristics of gastric cancer in Israel, in comparison to with a Western population. The authors indicated that results unique to the Israeli population were increased incidence of gastric cancer in Ashkenazi Jews and a high incidence of second primary malignancy and family history of cancer. In both study populations, there was no predominance of proximal gastric cancer (10). In the current study, no significant differences were identified between Jewish and Arab populations, or between gastric and GEJ adenocarcinoma patients, with regard to HER2 expression. The median age at diagnosis was similar to that observed in other studies (10,11). However, HER2 positivity in Ashkenazi Jews was not evaluated due to the small number of patients. The rate of HER2 positivity identified in the current study is within the lower range published in the literature (11-13). Tumor heterogeneity is more common in gastric cancer patients than in breast cancer patients, with regard to HER2 scoring. Therefore, a significant number of patients may be missed, as was demonstrated in a previous validation study (12).
Further examination of uncertain cases in relation to tumor heterogeneity, type, grade, location and distribution of polysomy did not provide valuable information for the validation of HER2 status (12). In the current study, all histological specimens were immunohistochemically stained for HER2 using anti c-erbB2 oncoprotein antibody (Dako). Several cases were further evaluated by the Ventana PATHWAY anti-HER-2/neu (4B5) antibody. Cases that demonstrated an IHC score of +2 were further evaluated using the HER2CISH ph Carmel (Dako). This was conducted similarly to the recommendations by Rüschoff et al, which suggest that IHC should be the initial testing methodology and FISH/silver in situ hybridization should be used to re-evaluate samples with an IHC score of +2 (14).

The clinical significance of cyclin D1 overexpression in gastric cancer is inconclusive (7); it has been demonstrated to be associated with poor differentiation, diffuse type lesions, signet ring cell carcinoma or lymph node involvement, and depth of invasion (15,16). In the present study, the majority of samples were cyclin D1-positive. Even when a threshold of 50% cell staining was applied to differentiate between positive and highly positive cyclin D1 staining, no correlation was identified between cyclin D1-positive staining and survival. Also, no correlation was demonstrated between HER2 status and cyclin D1. There were certain differences in the extent of cyclin D1 staining between the primary biopsy and the full surgical specimen; we propose this was a consequence of heterogeneity for cyclin D1 staining in the full surgical specimen. Therefore, in this case, a primary biopsy specimen taken from a limited location within the tumor may not accurately represent the extent of cyclin D1 staining. Differences in immunostaining between the primary biopsy and the full surgical specimen may also be attributed to differences in fixation between smaller and larger sized tissue samples (17). However, this is less likely in our case, since no differences in the interpretation of HER2 immunostaining were noted.

According to the ToGA trial (a large, multicenter, phase III, randomized controlled trial), trastuzumab in combination with chemotherapy is the new standard option for patients with HER2+ advanced gastric and GEJ adenocarcinoma, due to its survival benefit (6). The independent prognostic value of HER2 overexpression, as identified in the current study as well as in others (4), raises the need for clinical evaluation of anti-HER2 monoclonal antibodies as a part of the adjuvant treatment protocol for gastric adenocarcinoma.

In conclusion, the rate of positive HER2 status in the current group of unselected Israeli patients with gastric and GEJ adenocarcinoma was relatively low, compared with that noted in the literature. Nevertheless, positive HER2 was associated with a poor prognosis in Cox regression multivariate analysis.

References
1. Israel National Cancer Registry: Cancer Incidence Tables: Stomach. http://abush.health.gov.il/download/sartan/Stomach.pdf. Accessed August 2009.
2. Slamon DJ, Godolphin W, Jones LA, et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712, 1989.
3. Scholl S, Beuzeboc P and Pouillart P: Targeting HER2 in other tumor types. Ann Oncol 12 Suppl 1: S81-87, 2001.
4. Chuá YC and Merrett ND: Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes - a systematic review. Int J Cancer 130: 2845-2856, 2012.
5. Tanner M, Hollmén M, Junttila TT, et al: Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 16: 273-278, 2005.
6. Bang YJ, Van Cutsem E, Feyereislova A, et al: ToGA Trial Investigators: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376: 687-697, 2010.
7. Weinberg RA: The retinoblastoma protein and cell cycle control. Cell 81: 323-330, 1995.
8. Yan B, Yau EX, Bte Omar SS, et al: A study of HER2 gene amplification and protein expression in gastric cancer. J Clin Pathol 63: 839-842, 2010.
9. Grabisch H, Sivakumar S, Gray S, Gabbert HE and Müller W: HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value - conclusions from 924 cases of two independent series. Cell Oncol 32: 57-65, 2010.
10. Dreznik A, Purim O, Idevliev E, et al: Gastric cancer: biology and clinical manifestations in Israel. J Surg Oncol 105: 316-322, 2012.
11. Giuffrè G, Ieni A, Barresi V, Caruso RA and Tuccari G: HER2 status in unusual histological variants of gastric adenocarcinomas. J Clin Pathol 65: 237-241, 2012.
12. Hofmann M, Stoss O, Shi D, et al: Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 52: 797-805, 2008.
13. Rüschoff J, Dietel M, Baretton G, et al: HER2 diagnostics in gastric cancer - guideline validation and development of standardized immunohistochemical testing. Virchows Arch 457: 299-307, 2010.
14. Rüschoff J, Hanna W, Biloux M, et al: HER2 testing in gastric cancer: a practical approach. Mod Pathol 25: 637-650, 2012.
15. Feakins RM, Nickols CD, Bidd H and Walton SJ: Abnormal expression of pRb, p16, and cyclin D1 in gastric adenocarcinoma and its lymph node metastases: relationship with pathological features and survival. Hum Pathol 34: 1276-1282, 2003.
16. Kishimoto I, Mitomi H, Ohkura Y, Kanazawa H, Fukui N and Watanabe M: Abnormal expression of p16(INK4a), cyclin D1, cyclin-dependent kinase 4 and retinoblastoma protein in gastric carcinomas. J Surg Oncol 98: 60-66, 2008.
17. Werner M, Chott A, Fabiano A and Battifora H: Effect of formalin tissue fixation and processing on immunohistochemistry. Am J Surg Pathol 24: 1016-1019, 2000.